Because larger mutation screenings—including RAS, BRAF, MET (mutations, amplifications), ERBB2 (mutations, amplifications), ALK (mutations) and ROS (mutations)—were shown to be useful in the management of lung cancer patients, targeted NGS is progressively replacing single gene testing methods. Here, MET is linked to lung cancer.